Key facts
- Wingor’s last known valuation is $18.2M (Mar 2019).
- Notable investors include Oriental Fortune Capital, Meilleure, Wuhan Hanshang Group Company, Zhonghe Ruimin Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Wingor
- ·The full record, as it builds
Funding rounds
No funding rounds for Wingor are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Wingor
Developer of cell biotechnology research and development. The company specializes in life science and cell biotechnology innovation research and development, transformational application research and technical services.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2013
- Employees
- 42
- Website
- wingor.net/
- Ownership
- Privately Held (backing)
Wingor doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Wingor shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Wingor in its N-PORT filings yet. We sweep new filings monthly.